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Scheme S1. Synthesis pathway of the monodisperse side-functionalized polysarcosine oligomers
The synthesis and characterization of compounds are further detailed below. The protocols for experiments in mice and rats were approved by the University of Lyon Animal Ethics
Committee. In vivo studies were performed at Antineo (Lyon, France -www.antineo.fr).
HPLC methods
HPLC Method 1: Agilent 1050 equipped with DAD detection. Mobile phase A was water and mobile phase B was acetonitrile. Column was an Agilent Zorbax SB-Aq 4.6x150mm 5µm (room temperature).
Gradient was 5%B to 95%B in 20 min, followed by a 5 min hold at 95%B. Flow rate was 1.5 mL/min.
UV detection was monitored at 214 nm.
HPLC Method 2: Agilent 1050 equipped with DAD detection. Mobile phase A was water and mobile phase B was acetonitrile. Column was an Agilent Zorbax SB-Aq 4.6x150mm 5µm (room temperature).
Gradient was 0%B to 50%B in 30 min, followed by a 5 min hold at 50%B. Flow rate was 1.0 mL/min.
UV detection was monitored at 214 nm. 
Tert-butyl ester removal
Fmoc-Sar-Sar-OtBu (2310 mg / 5.27 mmol) was dissolved in 20 mL of DCM and 8. were swollen in 10 mL of anhydrous DCM for 10 min. Fmoc-Sar-OH (1.2 eq), previously dissolved in 10 mL of dry DCM, was added onto the resin. DIPEA (5 eq) was added and the reaction vessel was agitated for 2 hours at room temperature. After draining, the resin was washed with DCM (3 times), DMF (2 times), DCM (3 times) and MeOH (2 times). The resin was dried under high vacuum overnight. Substitution level was assessed from the weight gain of the resin and/or from Fmoc cleavage test (absorbance measurement at 301 nm) and was found to be quasi-quantitative (usually 0.95-1.1 mmol/g). Resin was stored at -20°C until further use.
Fmoc-Sar-Sar-OH coupling procedure
Resin was treated with 20% piperidine in DMF (1 mL per 100 mg of resin) for 2 times 15 min at room temperature. The resin was then washed with DMF (4 times) and DCM (4 times). To the resin was added a solution of Fmoc-Sar-Sar-OH (3 eq), HATU (2.85 eq) and DIPEA (6 eq) in DMF (1 mL per 100 mg of resin). The reaction vessel was agitated for 2 hours and the resin was extensively washed with DMF (5 times) and DCM (5 times). The resin was treated with 20% piperidine in DMF (1 mL per 100 mg of resin) for 2 times 15 min at room temperature. The resin was then washed with DMF (4 times) and DCM (4 times). The resin was dried under vacuum and stored at -20°C until further use.
Elongation of polysarcosine
Elongation of the polysarcosine oligomer was performed until the desired length was obtained, by alternating bromoacetylation and amine displacement steps. The bromoacetylation step was performed by adding 10 eq of bromoacetic acid and 13 eq of diisopropylcarbodiimide in DMF (2 mL per 100 mg of resin). The mixture was agitated for 30 min, drained and washed with DMF (4 times).
For the amine displacement step, a 40% (wt) methylamine in water solution was added (1.5 mL per 100 mg of resin) and the vessel was shaken for 30 min, drained and washed with DMF (4 times) and DCM (4 times).
Introduction of the azido group
10 eq of bromoacetic acid and 13 eq of diisopropylcarbodiimide in DMF (2 mL per 100 mg of resin)
were added onto the resin and the mixture was agitated for 30 min, drained and washed with DMF (4 times). A 3 molar solution of 2-azidoethan-1-amine 1 in DMF was added (1 mL per 100 mg of resin) and the vessel was shaken for 45 min, drained and washed with DMF (4 times) and DCM (4 times).
4-maleimidophenylacetic acid coupling
To the resin was added a solution of commercially available 4-maleimidophenylacetic acid (5 eq), COMU (4.9 eq) and DIPEA (4.9 eq) in DMF (1 mL per 100 mg of resin). The reaction vessel was agitated for 90 min and the resin was washed with DMF (3 times) and DCM (3 times). Cleavage of the compound of interest from the resin was performed using a 1% TFA in DCM (v/v) solution under agitation for 5 minutes (repeated twice). Resin was filtered and volatiles were removed under reduced pressure to afford a solid crude.
Purification
PSAR compounds were purified on Interchim ® RP-AQ (30µm) cartridges. Mobile phase A was water + 0.1% TFA and mobile phase B was acetonitrile + 0.1% TFA. The gradient ranged from 0 to 30% B. 
Fmoc-Sar-Sar-OH coupling procedure
To the resin was added a solution of Fmoc-Sar-Sar-OH (4 eq), HATU (3.9 eq) and DIPEA (8 eq) in DMF (1 mL per 100 mg of resin). The reaction vessel was agitated for 2 hours and the resin was extensively washed with DMF (4 times) and DCM (4 times). The resin was treated with 20% piperidine in DMF (1 mL per 100 mg of resin) for 2 times 15 min at room temperature. The resin was then washed with DMF (4 times) and DCM (4 times).
Elongation of polysarcosine compounds
Elongation of the polysarcosine oligomer was performed until the desired length was obtained, by alternating bromoacetylation and amine displacement steps, as already described above.
4-maleimidophenylacetic acid coupling
4-maleimidophenylacetic acid was coupled following the procedure described above. Cleavage of the compound from the resin was performed using 5 mL of a TFA/DCM (50:50) solution for 30 minutes under agitation at room temperature. The process was repeated once and the pooled filtrates were evaporated under reduced pressure to give a solid crude that was purified on Interchim ® RP-AQ (30µm) cartridges as described in the above section. were swollen in 4 mL of anhydrous DCM for 10 min. Fmoc-PEG12-COOH (PurePEG LLC., 1.2 eq), previously dissolved in 2 mL of dry DCM, was added onto the resin. DIPEA (3 eq) was added and the reaction vessel was agitated for 1 hour at room temperature. 300µL of MeOH was added to quench unreacted resin. After 10 min of shaking, the solution was drained and the resin was washed with DMF (3 times) and DCM (3 times). The resin was treated with 20% piperidine in DMF (1 mL per 100 mg of resin) for 2 times 15 min at room temperature. The resin was then washed with DMF (4 times) and DCM (4 times).
Introduction of the azido group
The bromoacetylation step was performed by adding 10 eq of bromoacetic acid and 13 eq of diisopropylcarbodiimide in DMF (2 mL per 100 mg of resin). The mixture was agitated for 30 min, drained and washed with DMF (4 times). For the amine displacement step, a 3 molar solution of 2-azidoethan-1-amine 1 in DMF was added (1 mL per 100 mg of resin) and the vessel was shaken for 45 min, drained and washed with DMF (4 times) and DCM (4 times). 
4-maleimidophenylacetic acid coupling

Step 2
110.8 mg (0.087 mmol) of starting material was dissolved in MeOH (10 mL) at 0°C. LiOH monohydrate (36.7 mg / 0.87 mmol) was dissolved in water (1 mL) and was slowly added to the reaction vessel.
After stirring at 0°C for 70 min, the mixture was neutralized with acetic acid (68.2 mg / 1.14 mmol) and 
Synthesis of polysarcosine-based drug-linkers (PSARn) by click chemistry
Alkyne-glucuronide-MMAE (1 eq; obtained as described above), PSARn-N3-phenyl-MAL (1.1 eq; obtained as described above) and tetrakis(acetonitrile)copper(I) hexafluorophosphate ( 
Synthesis of polyethyleneglycol-based drug-linker PEG12 by click chemistry
Alkyne-glucuronide-MMAE (obtained as described above) and PEG12-N3-phenyl-MAL (obtained as described above) were reacted and purified as described in the above section 4, using NMP/DCM ( 
Synthesis of linear negative control drug-linker PSAR12L by click chemistry
Alkyne-glucuronide-MMAE (obtained as described above) and N3-PSAR12-phenyl-MAL (obtained as described above) were reacted and purified as described in the above section 4, using NMP/DCM ( 
Synthesis of negative control drug-linker PSAR0 by click chemistry
Alkyne-glucuronide-MMAE (obtained as described above) and N-(2-azidoethyl)-2-(4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)phenyl)acetamide (obtained as described above) were reacted and purified as described in the above section 4, using ACN/NMP/DCM 
Preparation of ADCs
A solution of trastuzumab (10 mg/mL in PBS 7.4 + 1 mM EDTA) was treated with 14 molar equivalent of tris(2-carboxyethyl)phosphine (TCEP) for 2 hours at 37°C. The fully reduced antibody was bufferexchanged with potassium phosphate 100 mM pH 7.4 + 1 mM EDTA by three rounds of dilution/centrifugation using Amicon 30K centrifugal filters device (Merck Millipore). 10 molar equivalents of drug-linker (from a 12 mM DMSO stock solution) was added to the antibody (residual DMSO <10% v/v). The solution was incubated 30 min at room temperature. The conjugate was bufferexchanged/purified with PBS 7.4 using PD MiniTrap G-25 columns (GE Healthcare) and was sterilefiltered (0.20µm PES filter). Conjugates were diluted at 5 mg/mL with PBS 7.4 and were incubated at 37°C for 48h to promote complete hydrolysis of the succinimidyl moiety. Final protein concentration
was assessed spectrophotometrically at 280 nm using a Colibri microvolume spectrometer device (Titertek Berthold). Mass recovery (yield) of the conjugation/purification procedure was routinely >90%.
Characterization of ADCs
RPLC-QToF
Thermo UltiMate 3000 UHPLC system + Bruker Impact II TM Q-ToF mass spectrometer. Mobile phase A was water + 0.1% formic acid and mobile phase B was acetonitrile + 0.1% formic acid. Column was an Agilent PLRP-S 1000Å 2.1x150mm 8µm (80°C). Gradient was 10%B to 50%B in 25 min. Flow rate was 0.4 mL/min. UV detection was monitored at 280 nm. The Q-ToF mass spectrometer was used in the m/z range 500-3500 (ESI + ). Data were deconvoluted using the MaxEnt algorithm included in the Bruker Compass ® software. ADC samples were diluted with H2O for injection (approx. 1.5 mg/mL final ADC concentration).
SEC
SEC was performed on an Agilent 1050 HPLC system having an extra-column volume below 15µL
(equipped with short sections of 0.12mm internal diameter peek tubing and a micro-volume UV flow cell). Column was an Agilent AdvanceBio SEC 300Å 4.6x150mm 2.7µm (maintained at room temperature). Mobile phase was 100 mM sodium phosphate and 200 mM sodium chloride (pH 6.8).
10% acetonitrile (v/v) was added to the mobile phase to minimize secondary hydrophobic interactions with the stationary phase and prevent bacterial growth. Flow rate was 0.35 mL/min. UV detection was monitored at 280 nm.
HIC
Hydrophobic interaction chromatography (HIC) was performed on an Agilent 1050 HPLC system.
Column was a Tosoh TSK-GEL BUTYL-NPR 4.6x35mm 2.5 µm (25°C). Mobile phase A was 1.5 M (NH4)2SO4 + 25 mM potassium phosphate pH 7.0. Mobile phase B was 25 mM potassium phosphate pH 7.0 + 15% isopropanol (v/v). Linear gradient was 0%B to 100%B in 10 min, followed by a 3 min hold at 100%B. Flow rate was 0.75 mL/min. UV detection was monitored at 220 and 280 nm.
PK studies in mice
ADCs were injected at 3 mg/kg in female SCID mice (4-6 weeks old -Charles River) via the tail vein (five animals per group, randomly assigned). Blood was drawn into citrate tubes via retro-orbital bleeding at various time points, processed to plasma and stored at -80°C until analysis. ADC concentration was assessed using a human IgG ELISA kit (Stemcell TM Technologies) according to the manufacturer's protocol. Standard curves of Trastuzumab were used for quantification.
Pharmacokinetics parameters (clearance and AUC) were calculated by two-compartmental analysis using Microsoft ® Excel ® software incorporating PK functions (add-in developed by Usansky et al.,
Department of Pharmacokinetics and Drug Metabolism, Allergan, Irvine, USA).
PK studies in rats
ADCs were injected at 3 mg/kg in female Sprague-Dawley rats (4-6 weeks old -Charles River) via the tail vein (three animals per group, randomly assigned). Blood was drawn into citrate tubes via retro-orbital bleeding at various time points, processed to plasma and stored at -80°C until analysis.
ADC concentration was assessed using a human IgG ELISA kit (Stemcell TM Technologies) according to the manufacturer's protocol. Standard curves of Trastuzumab were used for quantification.
